Centessa Pharmaceuticals Q2 2024 GAAP EPS $(0.40) Misses $(0.39) Estimate
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals (NASDAQ:CNTA) reported a Q2 2024 GAAP EPS of $(0.40), missing the analyst consensus estimate of $(0.39) by 2.56%.
August 13, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Centessa Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.40), missing the analyst consensus estimate of $(0.39) by 2.56%.
The reported EPS miss, although slight, is likely to negatively impact investor sentiment and could lead to a short-term decline in CNTA's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100